VIRIDIAN THERAPEUTICS INC (VRDN) Stock News

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

Mentions: NICE AI CABA EWCZ

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Mentions: AMGN

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

The results are also promising for the next-generation version of that drug.

Mentions: AMGN

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024